Safety and preliminary efficacy of talimogene laherparepvec (T-VEC) in combination (combo) with pembrobrolizumab (Pembro) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): A multicenter, phase 1b study (MASTERKEY-232).

Kevin J. Harrington,Anthony Kong,Nicolas Mach,Tamara Rordorf,Jesus Corral Jaime,Vittoria Espeli,Sheryl Treichel,Burak Gumuscu,Jenny J. Kim,Jason Chesney

Safety and preliminary efficacy of talimogene laherparepvec (T-VEC) in combination (combo) with pembrobrolizumab (Pembro) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): A multicenter, phase 1b study (MASTERKEY-232).

2018

Kevin J. Harrington
Anthony Kong
Nicolas Mach
Tamara Rordorf
Jesus Corral Jaime
Vittoria Espeli
Sheryl Treichel
Burak Gumuscu
Jenny J. Kim
Jason Chesney

6036Background: We evaluated the safety and efficacy of the combo of T-VEC, the first FDA-approved oncolytic immunotherapy that enhances systemic antitumor immune responses, and Pembro, an immune c...

Keywords:

Carcinoma
Talimogene laherparepvec
Pathology
Cancer research
Medicine
head and neck
Immunotherapy
in patient
Oncology
Immune system
basal cell
Oncolytic virus
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations